NVAX SEC Filings
SEC filings for NVAX. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.
| Form | Filed | Accession |
|---|---|---|
| 8-KAINovavax reported Q3 2026 total revenue of $68 million (down 3% from $70 million) and a net loss of $31 million, versus a $202 million loss a year earlier. | Nov 5, 2026 | 0001000694-26-000021EDGAR |
| 8-K | Oct 29, 2026 | 0001104659-26-120221EDGAR |
| 8-K | Aug 6, 2026 | 0001000694-26-000019EDGAR |
| 8-KAINovavax held its Annual Meeting on June 18, 2026, with 99,118,766 of 164,427,429 outstanding shares (about 60.3%) present. | Jun 23, 2026 | 0001104659-26-076648EDGAR |
| 8-KAINovavax reported Q1 2026 total revenue of $140 million, down 79% from $667 million in Q1 2025, which included $603 million of non-cash revenue from the close-out of two APAs. | May 6, 2026 | 0001628280-26-030924EDGAR |
| 8-K | Feb 26, 2026 | 0001000694-26-000011EDGAR |
| 8-K | Jan 20, 2026 | 0001104659-26-004785EDGAR |
| 8-KAINovavax furnished an investor presentation for the 44th J.P. | Jan 12, 2026 | 0001104659-26-002725EDGAR |
| 8-K | Nov 6, 2025 | 0001000694-25-000048EDGAR |
SEC filings for companies related to NVAX
Never miss a NVAX filing.
Get an email when NVAX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.